Articles

Selinexor, pomalidomide, and dexamethasone led to high response rates in patients with multiple myeloma who were refractory to lenalidomide and had not been previously treated with pomalidomide. Read More ›

After more than 4 years of median follow-up, treatment with daratumumab, lenalidomide, and dexamethasone continues to improve progression-free survival compared with lenalidomide and dexamethasone alone in relapsed/refractory multiple myeloma, with deep and durable responses. Read More ›

Despite safety concerns related to daratumumab, a meta-analysis of 5 large randomized controlled trials showed no significant increase in treatment delays, trial discontinuation, or treatment-related deaths in patients with untreated or relapsed/refractory multiple myeloma who received the drug. Read More ›

Researchers report promising findings for a novel quad regimen, D-RVd, compared with RVd in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem-cell transplant. Read More ›

A retrospective analysis suggests improved survival outcomes with selinexor plus dexamethasone compared with standard treatments in triple-class relapsed or refractory multiple myeloma (RRMM). Read More ›

New data suggest that combinations using a subcutaneous (SC) co-formulation of daratumumab with recombinant human hyaluronidase have similar clinical activity and safety as intravenous daratumumab in patients with newly diagnosed multiple myeloma (MM). Read More ›

This first-in-human study shows that AMG 420, a BiTE antibody that directs the immune system to target B-cell maturation antigen (BCMA) on the tumor cell and CD3 on T-cells, may be effective and safe. Read More ›

Researchers report positive data for patients with relapsed or refractory multiple myeloma (RRMM) and extramedullary disease in the phase 2 HORIZON study of melflufen plus dexamethasone. Read More ›

This phase 1 study demonstrates that CT053, a B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell product, is effective and safe in patients with multiply relapsed multiple myeloma (MM). Read More ›

This study reports successful administration of intravenous daratumumab over 90 minutes for patients with relapsed or refractory multiple myeloma (RRMM). Read More ›